HYNES CONVENTION CENTER

Boston, Massachusetts
March 4–7, 2018

 

Scientific Program Committee

Program Committee Chairs

Susan P. Buchbinder, MD, Chair

Dr Buchbinder is Director of Bridge HIV at the San Francisco Department of Public Health and Associate Clinical Professor of Medicine, Epidemiology, and Biostatistics at the University of California San Francisco (UCSF). She focuses her research on risk factors for HIV acquisition and interventions to prevent HIV infection, including HIV vaccines, preexposure prophylaxis, behavioral interventions, rectal microbicides, and combination modalities. She serves in leadership positions in HVTN and HIV Prevention Trials Network (HPTN), and has participated in numerous National Institutes of Health (NIH) and UCSF advisory committees.

Judith S. Currier, MD, MSc, Vice Chair

Dr Currier is Professor of Medicine, Chief of the Division of Infectious Diseases, and Codirector of the Center for AIDS Research and Education (CARE) at University of California Los Angeles (UCLA). She is Vice Chair of the NIH-sponsored ACTG. Her research has focused on long-term complications of HIV disease with an emphasis on sex differences and antiretroviral therapy, cardiovascular disease, and women’s health.

Richard A. Koup, MD, Vice Chair

Dr Koup is Senior Investigator, Chief of the Immunology Laboratory, and Deputy Director of the Vaccine Research Center within NIAID in Bethesda, Maryland. His research involves the characterization of T and B cell factors involved in protective immunity against HIV infection, in order to inform the development of vaccines. He has published more than 240 manuscripts on this and related topics and has mentored more than 35 graduate and postgraduate students in his career.

Program Committee Members

Elaine J. Abrams, MD

Dr Abrams is Professor of Pediatrics and Epidemiology at Columbia University Medical Center and Senior Research Director at the International Center for AIDS Care and Treatment Programs (ICAP) in New York, New York. Her research interests focus on the prevention and treatment of HIV infection in infants, children, and adolescents. Her work includes clinical trials of antiretroviral drug efficacy, testing strategies to optimize treatment outcomes, and evaluating models of HIV care and service delivery.

Adaora Adimora, MD

Dr Adimora is Professor of Medicine and Epidemiology at the University of North Carolina at Chapel Hill. Her research focuses on the epidemiology of HIV and STDs among minority populations, with particular attention to the role of social, political, and economic factors in vulnerability to HIV and related outcomes. She is PI of the Women’s Interagency HIV Study’s UNC site.

Galit Alter, PhD

Dr Alter is Associate Professor of Medicine at the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard, in Boston, Massachusetts, where she studies the antiviral and antimicrobial role of antibodies against a spectrum of infections, including HIV, as well as the pathways by which protective humoral immune responses may be delivered via vaccination or through the delivery of monoclonal therapeutics.

Constance A. Benson, MD

Dr Benson is Professor of Medicine, Senior Attending Physician in the Division of Infectious Diseases, Director of the Infectious Diseases Training Program, Director of the Antiviral Research Center, and Principal Investigator of the CD4 Collaborative HIV Clinical Trials Unit at University of California San Diego (UCSD). She is an internationally recognized researcher and clinician and has worked in the field of HIV/AIDS since 1984. Most recently her research has focused on the treatment and prevention of HIV-associated tuberculosis (TB), the development of rapid point-of-care diagnostic assays for resource-limited settings, and new antiretroviral drug development.

Paul Bieniasz, PhD

Dr Bieniasz is a professor at the Aaron Diamond AIDS Research Center and the Rockefeller University in New York. His research interests include the mechanism of viral particle genesis, intrinsic and innate barriers to retrovirus replication and the development of animal models for HIV/AIDS. He is an investigator of the Howard Hughes Medical Institute and and an elected member of the American Academy of Microbiology.

Connie L. Celum, MD, MPH

Dr Celum is Professor of Global Health and Medicine, Adjunct Professor of Epidemiology and Director of the International Clinical Research Center in the Department of Global Health at University of Washington. Dr Celum is an infectious disease epidemiologist with a focus on HIV prevention. She has led multi-center HIV prevention efficacy trials, including genital herpes suppression for prevention of HIV acquisition (HPTN 039) and prevention of HIV transmission and disease progression in HIV serodiscordant couples (Partners in Prevention HSV/HIV Transmission Study). Dr Celum co-led the Partners PrEP Study a 3 arm trial of tenofovir-based pre-exposure antiretroviral prophylaxis among HIV serodiscordant couples in Kenya and Uganda and a demonstration project of ARV-based prevention in serodiscordant couples in Kenya and Uganda (the Partners Demo project). Dr Celum is co-leading implementation science research about PrEP implementation for young women in Kenya and South Africa (3P and POWER studies), and combination HIV prevention studies with decentralized ART initiation in Uganda and South Africa (the DO-ART study).

Richard E. Chaisson, MD

Dr Chaisson is Professor of Medicine, Epidemiology, and International Health, Director of the Center for Tuberculosis Research, and Director of the Center for AIDS Research at The Johns Hopkins University School of Medicine and Bloomberg School of Public Health in Baltimore, Maryland. He is Chair of the Tuberculosis Transformative Science Section of the AIDS Clinical Trials Group (ACTG) and his research interests focus on tuberculosis and HIV infection, including global epidemiology, clinical trials, diagnostics, and public health interventions.

Nicolas Chomont, PhD

Dr Chomont is an assistant professor in the Department of Microbiology and Immunology at the Université de Montréal–CHUM Research Center. His research focus on the characterization of the reservoirs for HIV during antiretroviral therapy. Dr Chomont is overseeing studies to unravel the molecular mechanisms involved in HIV latency and to develop novel therapeutic strategies aimed at reducing the size of the HIV reservoir.

John M. Coffin, PhD

Dr Coffin is Professor of Molecular Biology and Microbiology at Tufts University in Medford, Massachusetts, and the founding Director of the National Cancer Institute (NCI) HIV Drug Resistance Program, to which he still serves as a consultant. His research interests revolve around obtaining a better understanding of the interaction of retroviruses with their host cells and organisms. He has contributed more than 125 articles to the scientific literature, largely on the subjects of mechanisms of replication of retroviruses and interaction of HIV with its human host.

Kevin M. De Cock, MD

Dr De Cock is Director of the Centers for Disease Control and Prevention (CDC) in Kenya. His research interests have been the clinical and public health aspects of HIV/AIDS in resource-limited settings, including HIV-associated tuberculosis. He previously served as Director of the CDC Division of HIV/AIDS Prevention, Surveillance, and Epidemiology, Director of the World Health Organization (WHO) Department of HIV/AIDS, and Director of the CDC Center for Global Health.

Wafaa M. El-Sadr, MD, MPH

Dr El-Sadr is Professor of Epidemiology and Medicine at Columbia University in New York, New York, and the founder and Director of ICAP at the Columbia Mailman School of Public Health, which is engaged in the design implementation and scale-up of HIV and related programs and research globally. Her research interests include prevention and management of HIV and aspects of implementation science that aim at generating knowledge to advance the health of populations.

Joseph J. Eron, Jr, MD

Dr Eron is a member of the Division of Infectious Diseases and the Institute for Global Health and Infectious Diseases and a tenured Professor of Medicine at University of North Carolina Chapel Hill. His research focuses on antiretroviral therapy for the treatment and prevention of HIV-1 infection and novel clinical interventions to impact the HIV-1 reservoir and enhance HIV-specific immunity. He is the Principal Investigator for the NIH-funded UNC Global HIV treatment and prevention Clinical Trials Unit and an active investigator in the ACTG and HPTN.

Courtney V. Fletcher, PharmD

Dr Fletcher is Professor and Dean at the University of Nebraska Medical Center College of Pharmacy in Omaha, Nebraska. His research interests are in the clinical pharmacology of antiviral agents, primarily those directed against HIV. He founded and directs the Antiviral Pharmacology Laboratory, which has developed state-of-the-art methods for the bioanalysis of antiretroviral drugs, uses modern data analysis methods to describe pharmacokinetic and pharmacodynamic characteristics, and integrates these data into treatment regimens for patients to improve safety and efficacy.

Huldrych F. Günthard, MD

Dr Günthard is Professor of Infectious Diseases in the Division of Infectious Diseases and Hospital Epidemiology at University Hospital Zurich, Switzerland. Since 2012, he has been President of the Swiss HIV Cohort Study, a long-term observational HIV cohort that started in 1988. His research focuses on antiretroviral treatment of HIV-1, emergence and transmission of HIV-1 drug resistance, studies of transmission biology and transmission of HIV-1 at the population level, HIV-host interactions with a focus on immune responses to HIV and the latent reservoir, and on general aspects of primary HIV-1 infection.

Timothy Hallett, PhD

Dr Hallett is Professor of Global Health in the Department of Infectious Disease Epidemiology at Imperial College London, England. His work centers on the development and application of mathematical models for interpreting surveillance data, analyzing trials, and planning interventions. He is Director of the HIV Modelling Consortium and Cochair of the UNAIDS Reference Group on Estimates, Modelling, and Projections.

Scott M. Hammer, MD

Dr Hammer is Harold C. Neu Professor of Medicine, Professor of Epidemiology, and Chief of the Division of Infectious Diseases at the Columbia University Medical Center/NewYork–Presbyterian Hospital in New York, New York. His major investigative interests have focused on antiretroviral therapeutics and preventative HIV vaccine development. He has been a long-standing investigator in the National Institute of Allergy and Infectious Diseases (NIAID)-sponsored ACTG and HVTN. Within the HVTN, he is a member of the Executive Management Team and a Principal Investigator in the Leadership and Operations Center.

Diane V. Havlir, MD

Dr Havlir is Professor of Medicine at UCSF and Chief of the HIV/AIDS Division at San Francisco General Hospital in San Francisco, California. Her research focus includes HIV and tuberculosis, antiretroviral treatment strategies, and epidemiology of HIV drug resistance. She coleads a long-standing multidisciplinary UCSF-Makerere University research collaboration focusing on epidemiologic, clinical, translational, and implementation science studies in HIV, TB, and malaria in Uganda.

Sharon L. Hillier, PhD

Dr Hillier is Professor of Obstetrics, Gynecology, and Reproductive Sciences and Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine, and a Senior Investigator at Magee-Womens Research Institute, in Pittsburgh, Pennsylvania. The primary focus of her research is reproductive infectious diseases, with an emphasis on the prevention of sexually transmitted infections including HIV. She is a Principal Investigator of the Microbicide Trials Network, 1 of 5 clinical trials networks funded by the NIH, focused on the treatment and prevention of HIV. In addition, she has done research in the area of contraceptive hormones and HIV risk, and the preclinical and early clinical development of novel formulations of antiretroviral drugs for the prevention of HIV.

James A. Hoxie, MD

Dr Hoxie is Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania in Philadelphia. His research interests include the basic mechanisms of HIV and SIV entry and interactions with CD4 and cellular coreceptors and understanding how the viral envelope glycoprotein contributes to immunodeficiency and evasion from host immune responses in viral pathogenesis. He is also Director of the Penn Center for AIDS Research and has a long-standing interest in interdisciplinary approaches to address the growing public health burden of HIV-associated malignancies.

Peter Hunt, MD

Dr Hunt is Associate Professor of Medicine in the HIV/AIDS division at UCSF. He studies the causes and consequences of immune activation in treated HIV infection in the context of pathogenesis-oriented observational studies and clinical trials. He also serves as Vice Chair of the Inflammation and End-Organ Disease Transformative Science Group in the ACTG.

Harold W. Jaffe, MD

Dr Jaffe is Associate Director of Science at the CDC in Atlanta, Georgia, and was formerly the Director of National Center for HIV/AIDS, Sexually Transmitted Disease (STD), and TB Prevention at the CDC. He was a member of the original CDC Task Force that was formed to investigate the HIV/AIDS epidemic in 1981. His current research interests include HIV epidemiology, HIV-related malignancies, and HIV care and treatment in the developing world.

Ilesh V. Jani, MD, PhD

Dr Jani is Director General of the Instituto Nacional de Saúde (National Institute of Health), Mozambique. His research interests involve HIV/AIDS vaccines and point-of-care laboratory tests, including the deployment of these technologies in resource-limited health systems. He is currently leading various projects in the areas of research, public health, and education with the objective of strengthening the health system in Mozambique.

Frank Kirchhoff, PhD

Dr Kirchhoff is Professor of Virology and Director of the Institute of Molecular Virology, Ulm, Germany. One of his main research interests is to elucidate how primate lentiviruses manipulate the immune system, cross species barriers, and cause disease. In addition, he is interested in the discovery of natural human factors that play a role in viral pathogenesis and transmission and in their optimization for novel therapeutic or preventive approaches.

Dennis L. Kolson, MD, PhD

Dr Kolson is Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. His basic research investigations are in the pathways of HIV-induced inflammation and immune activation in neurodegeneration and in identifying host targets for neuroprotection strategies. He serves as scientific advisor and Steering Committee member for the NIH National NeuroAIDS Tissue Consortium, and as the Penn AIDS Clinical Trials Unit site Neurology Principal Investigator for neuroprotection trials.

Hermione Lyall, MD

Dr Lyall is Pediatric Infectious Diseases consultant at Imperial Healthcare National Health Service Trust in London, England, where she leads the Family HIV clinic at St Mary's Hospital. Her main areas of research and education are preventing mother-to-child transmission and pediatric HIV. She is a member of the Steering Committee of the Paediatric European Network for the Treatment of AIDS (PENTA), and she was the Principal Investigator on the recently completed KONCERT (Kaletra ONCE Daily Randomized Trial) trial (PENTA 18). She instigated the PENTA Tr@inforPedHIV online and residential HIV training course, which has helped train many healthcare workers around the world on HIV care in children.

James McIntyre, MBChB, FRCOG

Dr McIntyre is Executive Director of the Anova Health Institute in Johannesburg, South Africa, Honorary Professor in the School of Public Health and Family Medicine at the University of Cape Town, and Vice Chair of IMPAACT.

John W. Mellors, MD

Dr Mellors is tenured Professor of Medicine and Chief of Infectious Diseases at the University of Pittsburgh School of Medicine and Executive Director of the HIV Program at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania. His areas of research interest are mechanisms of HIV drug resistance, antiretrovirals to prevent HIV-1 infection, persistent reservoirs of HIV-1, and innovative approaches to cure HIV infection. He directs the virology cores for the ACTG and the Microbicide Trials Network and is an elected member of the Association of American Professors.

Ronald T. Mitsuyasu, MD

Dr Mitsuyasu is Professor of Medicine in the Division of Hematology-Oncology at the Geffen School of Medicine at UCLA and Director of the UCLA CARE Center. He has been a clinical investigator in AIDS and HIV since 1981, conducted trials of immune-based therapies, and more recently, of gene therapy for HIV. He is the Group Chairman of the NCI-funded AIDS Malignancy Consortium (AMC), which is involved in conducting clinical trials of new treatments for HIV-associated malignancies in the United States and in Africa.

Nelly R. Mugo, MBCHB, MPH

Dr Nelly Mugo is a member of the Center for Clinical Research (CCR) at the Kenya Medical Research Institute (KEMRI), Nairobi, Kenya. She is the head of the Sexual Reproductive Adolescent Child Health Research Program (KEMRI) and leads a clinical trial team, Parters in Health Research and Development in Thika, Kenya. Her research focuses on HIV prevention working with HIV serodiscordant couples and young women, prevention of cervical cancer and other areas of reproductive health.

Landon Myer, MD, PhD

Dr Myer is Professor and Head of the Division of Epidemiology and Biostatistics in the School of Public Health and Family Medicine at the University of Cape Town, South Africa, and Director of the Centre for Infectious Diseases Epidemiology and Research. Over the past 15 years his program of research has focused on the impact of HIV on women’s, maternal and child health across South and southern Africa, with projects integrating clinical science and health systems perspectives.

Julie M. Overbaugh, PhD

Dr Overbaugh is a Member of the Division of Human Biology and Program in Epidemiology at the Fred Hutchinson Cancer Research Center in Seattle, Washington. Her research focuses on the biology of HIV transmission and the role of antibodies in protection from infection. The studies of her lab, which focus on populations at high risk for HIV, including infants and women, are conducted with the Kenya Research Program, an international, interdisciplinary team that has worked together for more than 2 decades.

Andrew N. Phillips, PhD

Dr Phillips is Professor of Epidemiology at University College London, England, where he coleads the HIV Epidemiology and Biostatistics Group in the Department of Infection and Population Health. He is involved in several HIV research activities: large observational cohorts of people with HIV, studies of transmission and sexual behavior, and randomized trials. He also works on modeling and health economic analyses to address public health questions, in the context of high- and lower-income settings.

Peter Reiss, MD, PhD

Dr Reiss is Professor of Medicine in the Department of Global Health and Division of Infectious Diseases at Academic Medical Center of the University of Amsterdam, the Netherlands. He is also Director of the Netherlands HIV Monitoring Foundation, which oversees the monitoring and evaluation of health outcomes in people with HIV in care in the Netherlands. He is the Principal Investigator of the AGEhIV Cohort Study which studies the epidemiology and pathogenesis of noncommunicable comorbidity in relation to aging in HIV.

Douglas D. Richman, MD

Dr Richman is Distinguished Professor of Pathology and Medicine at the UCSD. His laboratory currently focuses on the natural history and molecular pathogenesis of HIV in a cohort of acutely infected patients. Additional virologic investigations include studies of HIV drug resistance, the pathogenetic consequences of virus replication in anatomic compartments, viral latency, and eradication strategies.

Jürgen Rockstroh, MD

Dr Rockstroh is Professor of Medicine in the Department of Medicine at the University of Bonn, Germany. His research interests involve clinical trials in HIV and hepatitis C virus (HCV) therapy as well as pathogenesis of acute HCV infection, particularly in HIV coinfection. He is the current Chair for the European AIDS Clinical Society coinfection guidelines as well as Chair of hepatitis research within the European AIDS Treatment Network (NEAT) ID Foundation.

Robert T. Schooley, MD

Dr Schooley is Professor of Medicine and Head of the Division of Infectious Diseases at UCSD. His research interests are in the areas of HIV and HCV pathogenesis and therapy and in the development of novel diagnostic technologies.

Guido Silvestri, MD

Dr Silvestri is Professor of Pathology and Laboratory Medicine at Emory University in Atlanta, Georgia, and Chief of the Division of Microbiology and Immunology at the Yerkes Primate Center. His research focuses on the pathogenesis, prevention, and therapy of HIV infection using nonhuman primate models. Key contributions to this area include the elucidation of the mechanisms responsible for the benign course of simian immunodeficiency virus (SIV) infection in natural hosts, and the development of novel techniques to manipulate the immune system in vivo in nonhuman primates.

Annette H. Sohn, MD

Dr Sohn is the Director of the TREAT Asia program in Thailand, and Vice President of Global Initiatives of amfAR, the Foundation for AIDS Research. She is also an Assistant Clinical Professor in the Department of Pediatrics at the University of California, San Francisco. She has been working in Asia for over 10 years, conducting clinical and epidemiologic HIV research involving infants, children, adolescents, and adults, in collaboration with a research network stretching across 58 institutions in 13 countries.

Serena S. Spudich, MD, MA

Dr Spudich is Associate Professor of Neurology and Chief of the Division of Neurological Infections and Global Neurology at Yale University in New Haven, Connecticut. Her clinical research has focused on HIV in the nervous system, particularly on effects of acute HIV infection and antiretroviral treatment on HIV neuropathogenesis and persistence. She collaborates with colleagues from multiple disciplines in clinical studies in urban centers in the United States and in international settings, currently serves as Chair of the Neurology Collaborative Science Group of the ACTG, and cares for HIV-infected patients with neurologic disorders.

Wesley I. Sundquist, PhD

Dr Sundquist is Cochair of Biochemistry at the University of Utah School of Medicine and Director of the NIH P50 Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH). His research focuses on the biochemistry, structural biology, and virology of HIV assembly, budding, and restriction, with a particular focus on host-virus interactions. He is a member of the American Academy of Arts and Sciences and the National Academy of Sciences.

David L. Thomas, MD

Dr Thomas is Stanhope Bayne-Jones Professor of Medicine and Chief of the Division of Infectious Diseases at The Johns Hopkins School of Medicine in Baltimore, Maryland. His clinical and research interests are focused on viral hepatitis, especially in HIV/HCV-coinfected individuals.

Alexandra Trkola, PhD

Dr Trkola is Professor of Medical Virology and Director of the Institute of Medical Virology at the University Zurich, Switzerland. Her research focuses on the humoral immune response to HIV and, in particular, neutralizing antibodies, mechanisms of HIV entry and transmission, inhibition of HIV entry, and virus escape.